{"acquired gene mutation": 1271.14, "cardiac failure": 5.21, "cardiomyopathy": 7.98, "cardiotoxicity": 36.48, "deep vein thrombosis": 2.39, "disease progression": 5.58, "drug resistance": 124.51, "egfr gene mutation": 698.54, "electrocardiogram qt prolonged": 8.94, "general physical health deterioration": 2.18, "interstitial lung disease": 17.17, "malignant neoplasm progression": 36.39, "malignant transformation": 844.08, "metastases to bone": 19.39, "metastases to central nervous system": 55.45, "metastases to liver": 19.35, "metastases to lung": 21.35, "metastases to lymph nodes": 19.85, "metastases to meninges": 257.26, "metastasis": 20.86, "mucosal inflammation": 8.02, "myelosuppression": 3.9, "off label use": 2.45, "paronychia": 85.56, "platelet count decreased": 2.67, "pleural effusion": 6.33, "pneumonitis": 44.73, "pulmonary embolism": 3.82, "respiratory failure": 5.22, "skin toxicity": 20.67, "thrombocytopenia": 5.34, "toxicity to various agents": 2.78}